Hitting the target in IDH2 mutant AML

被引：3
|
作者：
Wouters, Bas J. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
BLOOD | 2017年 / 130卷 / 06期
关键词：
DIFFERENTIATION; LEUKEMIA; CELLS;
D O I：
10.1182/blood-2017-06-790394
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Stein et al(1) demonstrate the feasibility and clinical efficacy of targeted inhibition of mutant isocitrate dehydrogenase 2 (IDH2) in patients with acute myeloid leukemia (AML). In a related paper, Amatangelo et al(2) investigate mechanisms of response in samples derived from the same patients.
引用
收藏
页码：693 / 694
页数：2
相关论文
共 50 条
  • [21] Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis
    Yoshimi, Akihide
    Lin, Kuan-Ting
    Wiseman, Daniel
    Intlekofer, Andrew M.
    Wang, Bo
    Pastore, Alessandro
    Rahman, Mohammad
    Lee, Stanley Chun-Wei
    Liu, Bo
    Micol, Jean-Baptiste
    De Botton, Stephane
    Penard-Lacronique, Virginie
    Shih, Alan H.
    Stein, Eytan M.
    Durham, Benjamin H.
    Inoue, Daichi
    Zhang, Xiao Jing
    Albrecht, Todd
    Chung, Young Rock
    Peng, Shouyong
    Buonamici, Silvia
    Palacino, James
    Smith, Peter
    Thompson, Craig B.
    Levine, Ross L.
    Wagner, Eric
    Krainer, Adrian R.
    Abdel-Wahab, Omar
    BLOOD, 2017, 130
  • [22] AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo
    Shih, Alan H.
    Shank, Kaitlyn R.
    Meydan, Cem
    Intlekofer, Andrew M.
    Ward, Patrick
    Thompson, Craig B.
    Melnick, Ari M.
    Travins, Jeremy
    Straley, Kim
    Gliser, Camelia
    Yen, Katherine
    Levine, Ross L.
    BLOOD, 2014, 124 (21)
  • [23] Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
    Borodovsky, Alexandra
    Seltzer, Meghan J.
    Riggins, Gregory J.
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (01) : 83 - 89
  • [24] The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
    Green, Claire L.
    Evans, Catherine M.
    Zhao, Lu
    Hills, Robert K.
    Burnett, Alan K.
    Linch, David C.
    Gale, Rosemary E.
    BLOOD, 2011, 118 (02) : 409 - 412
  • [25] Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 (m IDH2) Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Tallman, Martin S.
    De Botton, Stephane
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Collins, Robert H.
    Stein, Anthony S.
    Xu, Qiang
    Tosolini, Alessandra
    Gupta, Ira
    Agresta, Samuel V.
    Stein, Eytan M.
    BLOOD, 2017, 130
  • [26] Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
    DiNardo, Courtney D.
    Venugopal, Sangeetha
    Lachowiez, Curtis
    Takahashi, Koichi
    Loghavi, Sanam
    Montalban-Bravo, Guillermo
    Wang, Xuemei
    Carraway, Hetty
    Sekeres, Mikkael
    Sukkur, Ameenah
    Hammond, Danielle
    Chien, Kelly
    Maiti, Abhishek
    Masarova, Lucia
    Sasaki, Koji
    Alvarado, Yesid
    Kadia, Tapan
    Short, Nicholas J.
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Patel, Bhumika
    Dezern, Amy
    Roboz, Gail
    Garcia-Manero, Guillermo
    BLOOD ADVANCES, 2023, 7 (11) : 2378 - 2387
  • [27] AML patients with IDH1 or IDH2 mutations treated with hypomethylating agents: A case series
    Benton, Christopher Brent
    Ravandi, Farhad
    Andreeff, Michael
    Kantarjian, Hagop
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
    Nassereddine, Samah
    Lap, Coen J.
    Haroun, Faysal
    Tabbara, Imad
    ANNALS OF HEMATOLOGY, 2017, 96 (12) : 1983 - 1991
  • [29] Rapid IDH1/IDH2 Mutation Assessment in Acute Myeloid Leukemia (AML) and Glioma
    Huynh, T.
    Zhang, L.
    Li, Y.
    Solis, J.
    Stanley, A.
    Jin, H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (11): : S163 - S164
  • [30] Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Levine, Ross L.
    Flinn, Ian W.
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Frankel, Arthur E.
    Stein, Anthony
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Willekens, Christophe
    Vyas, Paresh
    Tosolini, Alessandra
    Xu, Qiang
    Knight, Robert D.
    Yen, Katharine E.
    Agresta, Sam
    de Botton, Stephane
    Tallman, Martin S.
    BLOOD, 2017, 130 (06) : 722 - 731
12345